Revenues grew 20.4% YoY to | 471 crore (I-direct estimate: | 455 crore) on the back of 18.6% growth in exports to | 287 crore (I-direct estimate: | 292 crore). Domestic sales grew 9.5% to | 162 crore (Idirect estimate: | 149 crore) .EBITDA margins increased 406 bps YoY to 35.4% (I-direct estimates: 32.0%) on account of gross margin expansion. Gross margins increased 532 bps YoY to 78.9% ((I-direct estimates: 75.5%). EBITDA increased 36.0% YoY to | 166.6 crore .Net profit increased 33.5% YoY to | 120 crore, (I-direct estimate: | 101 crore) on the back of a robust operational performance. ICICI Securities Limited maintain target of | 1780 based on 28x FY18E EPS of | 63.5. At the current level, the stock has already factored in the near term upside.Trendlyne has 6 reports on AJANTPHARM updated in the last year from 2 brokers with an average target of Rs 1712. Brokers have a rating for AJANTPHARM with 1 downgrade in past 6 months and 1 price downgrades,1 price upgrade in past 1 Year.